McDermott + Bull has successfully placed Kevin Belteau as Vice President (VP) of Clinical Affairs at enVVeno Medical. Kevin will develop, implement, and execute the company’s U.S. clinical trial strategy, ensuring the highest possible performance of clinical affairs deliverables to achieve enVVeno’s clinical initiatives. He will be a road warrior, visiting clinical sites, promoting patient enrollment, monitoring progress, managing contract research organizations, and ensuring clinical trial data is gathered in a timely manner as well as in accordance with FDA regulations.

Kevin spent 18 years at Medtronic, helping to push groundbreaking therapies through the clinical study process. He has built a strong background in numerous therapies and worked with care providers throughout the industry. Additionally, Kevin is a clinical operations leader which is showcased in his experience working with some of the most preeminent institutions in the United States.

enVVeno Medical is an Irvine, California-based, late clinical-stage medical device company focused on the advancement of innovative bioprosthetic solutions to improve the standard of care in the treatment of venous disease. Implanted into the femoral vein, enVVeno’s VenoValve is designed to act as a one-way valve, helping restore proper blood flow in the leg. The VenoValve is currently being evaluated in the SAVVE pivotal study with data expected in late 2022.

This executive search was completed by McDermott + Bull Partner Jake Vander Zanden, Director Jessica Combs, and Research Manager Rachel Terry Simonsen.